Zepbound (Tirzepatide)

Zepbound (tirzepatide) delivers the highest FDA-approved weight-loss efficacy ever recorded, with patients losing an average of 20.9% of body weight — about 48 pounds — at the 15 mg dose in the SURMOUNT-1 trial. This first-in-class dual GIP/GLP-1 receptor agonist outperforms #2 Wegovy by engaging the GIP pathway to enhance insulin sensitivity and energy expenditure. Data from the 72-week SURMOUNT-2 trial in patients with type 2 diabetes showed 12-15% weight loss, significantly exceeding any comparator. Approved in December 2024, it is also the only prescription medication to treat moderate-to-severe obstructive sleep apnea in adults with obesity, reducing apnea events by 25-29 per hour versus placebo. A 2026 monthly KwikPen delivers four doses via a single device, and pricing starts at $299 per month through LillyDirect, with savings cards lowering costs to $25 for eligible patients.